Solange Peters, MD, PhD

Articles

Unmet Needs in NSCLC Therapy

October 17th 2022

Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.

The Role of Adjuvant Immunotherapy in the Treatment of Resectable NSCLC

October 17th 2022

Vamsidhar Velcheti, MD, summarizes recent data on adjuvant immunotherapy treatment in resectable NSCLC.

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The NEOCoast Trial

October 17th 2022

Dr Myung-Ju Ahn describes the unique design and outcomes of the NEOCoast study that is evaluating immunotherapy regimens in the neoadjuvant and adjuvant settings.

Major Adverse Events of Anti-HER2 Therapies

October 10th 2022

Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.

HER2-Targeted Therapies in NSCLC

October 10th 2022

Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.

Optimizing the Role of Neoadjuvant Immunotherapy in Resectable NSCLC

October 7th 2022

Drs Vamsidhar Velcheti and Solange Peters discuss the optimum length for immunotherapy treatment in resectable NSCLC, highlighting the issue of payer authorizations.

Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials

October 7th 2022

Oncologists explain data from the NADIM II and AEGAN clinical trials investigating treatments for neoadjuvant immunotherapy in resectable NSCLC.

Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC

October 4th 2022

Solange Peters, MD, PhD, presents the case of a 72-year-old man with HER2-amplified NSCLC and starts a discussion on the recommended treatment plans.

Current Treatment Options in NSCLC

October 4th 2022

Dr Mark A Socinski reviews the currently available treatment options for NSCLC, including targeted therapies.

Testing Patients with NSCLC for HER2 Mutations

September 29th 2022

Anil Vachani, MD, MS, explains whether he orders biomarker testing for all patients with HER2-mutated NSCLC.

The Role of HER2 Alterations in NSCLC

September 29th 2022

Drs Allen and Socinski discussion the role of HER2 alterations in NSCLC and how it differs from breast cancer.

The Role of Neoadjuvant Immunotherapy in the Treatment of Resectable NSCLC

September 28th 2022

Myung-Ju Ahn, MD, summarizes the role of neoadjuvant immunotherapy in early-stage NSCLC treatment.

Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)

September 28th 2022

Melissa Johnson, MD, and Solange Peters, MD, review the available treatment options for stage I – III non-small cell lung cancer (NSCLC) and how the ESMO guidelines of patient management differ from the NCCN guidelines.

HER2 Alterations in NSCLC: Clinical Scenario

September 20th 2022

Dr Solange Peters shares the molecular testing results for the patient in the presented clinical scenario.

Liquid vs Solid Tumor Biopsies in NSCLC

September 20th 2022

Mark A. Socinski, MD, debates the merits of liquid versus tissue tumor biopsies in NSCLC biomarker testing.

Approaches to Biomarker Testing in NSCLC

September 12th 2022

Timothy Craig Allen, MD, JD, FCAP, explains how he approaches biomarker testing in NSCLC and what testing he would have ordered in the presented scenario.

Biomarker Testing in NSCLC: Clinical Scenario

September 12th 2022

A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.

Gathering Insights in Gynecologic, Lung, and GI Cancers From ESMO 2022: Drs Matulonis, Peters, and Janjigian

September 11th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in Metastatic NSCLC

August 29th 2022

Dr Solange Peters reviews data from POSEIDON on combination durvalumab, tremelimumab, and chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC) that were recently presented at the 2022 World Conference on Lung Cancer.

Dr. Peters Discusses Ongoing Research With Trastuzumab Deruxtecan in NSCLC

July 2nd 2020

Solange Peters, MD, PhD, discusses ongoing research with fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) in patients with HER2-mutated non–small cell lung cancer.